Arlington Trust’s Intellia Therapeutics NTLA Stock Holding History

Arlington Trust’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-24	Closed	-$732	–	759
2023 Q4	$732	Buy	+24	New	+$690	﹤0.01%	861

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arlington Trust's NTLA Position: Q1 2024 in Review

Arlington Trust sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 24 shares — an estimated $732 sold.

Arlington Trust first reported a position in NTLA in Q4 2023 and held it in 1 quarter. The position peaked at $732 in Q4 2023. 284 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

Arlington Trust reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
Arlington Trust sold 24 Intellia Therapeutics shares in Q1 2024, an estimated $732.
Arlington Trust first reported a position in Intellia Therapeutics in Q4 2023 and held it in 1 quarter.
Arlington Trust's Intellia Therapeutics position peaked at $732 in Q4 2023.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Arlington Trust's 13F filing for Q1 2024, filed 16 Apr 2024.